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Intercellular interactions are essential for basic cellular activities and errors in either receiving or transferring these
signals have shown to cause pathological conditions. These signals are not only regulated by membrane surface
molecules but also by soluble secreted proteins, thereby allowing for an exquisite coordination of cell functions.
Exosomes are released by cells upon fusion of multivesicular bodies (MVB) with the plasma membrane. Their
envelope reflects their cellular origin and their surface and internal contents include important signaling
components. Exosomes contain a wide variety of proteins, lipids, RNAs, non-transcribed RNAs, miRNAs and small
RNAs that are representative to their cellular origin and shuttle from donor cells to recipient cells. The exosome
formation cargo content and delivery is of immense biological interest because exosomes are believed to play major roles
in various pathological conditions, and therefore provide unique opportunities for biomarker discovery and development
of non-invasive diagnostics when examined in biological fluids such as urine and blood plasma. For example, circulating
miRNAs in exosomes have been applied as functional biomarkers for diagnosis and outcomes prediction, while synthetic
miRNAs in polymer-based nanoparticles are applicable for therapeutics. This review provides insights into the composition
and functional properties of exosomes, and focuses on their potential value as diagnostic markers in the context of
cardiovascular disease risk estimates in children who suffer from conditions associated with heightened prevalence of
adverse cardiovascular disease, namely obesity and sleep-disordered-breathing.Cardiovascular disease risk in children: obesity and
obstructive sleep apnea as prototypic risk factors
Cardiovascular diseases (CVDs) are the major source of
global morbidity and death and more people die annually
from CVDs that from any other disease. With the in-
creased worldwide prevalence of obesity, widely regarded
as an independent risk factor for a range of chronic dis-
eases including type 2 diabetes and cardiovascular disease
[1], a heightened morbidity and mortality from many car-
diovascular conditions including hypertension, dyslipid-
emia, and coronary artery disease has emerged [2,3].
In children, obesity is associated with increased risk for
multifaceted derangements in metabolic and cardiovascu-
lar function, including endothelial dysfunction (ED) [4-6].
In general terms, overweight children are more likely to
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article, unless otherwise stated.an array of conditions that would normally be only found
in older obese adults [7]. Recently, we have reported that
obesity in children is associated with an increased risk for
the development of ED, even prior to the onset of hyper-
tension [5]. A recent statement by the American Heart
Association has clearly identified the marked increases in
long-term cardiovascular risk associated with childhood
obesity [8]. Indeed, even short periods of overweight or
obesity during childhood have been linked to earlier mor-
tality in adulthood [9]. Therefore, early detection of chil-
dren at risk for such adverse outcomes would be critically
important to enable a more personalized intervention
aiming at CVD risk reduction. Although measurement of
24-hour systemic blood pressure, assessment of intima-
media thickness and of endothelial function have all been
advocated as potentially providing approaches for CVD
risk stratification, their implementation in the clinical set-
ting is fraught with objective difficulties that preclude their
universal implementation [10,11]. Thus, delineation of
more readily detectable biomarkers would definitely be de-
sirable. To this effect, assays of hsCRP have unfortunately
failed to deliver with sufficiently predictive precision,ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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curate predictive approaches of CVD risk in pediatric pop-
ulations [12-14].
Characteristics of biomarkers
To enable the use of exosomal contents to serve as useful
and implementable clinical biomarkers, several conditions
need to be met. Indeed, a biomarker must be accurate,
sensitive and specific; it needs to be altered in the relevant
disease, and be able to discriminate between healthy and
diseased subjects; quantification of the biomarker should
be reliable and reproducible; the biomarkers should be
consistent in different circumstances at different times,
and the results from biomarker assays should be easy to
interpret. A biomarker for diagnostic purposes should
ideally be obtained from readily accessible body fluids,
such as blood plasma, urine, and saliva and provide the
clinicians with diagnostic information and aid in the med-
ical decision making process [15-17].
Several circulating miRNAs in plasma have been success-
fully identified as biomarkers for a number of diseases in-
cluding oncological and non-oncological conditions [18-20],
and undoubtedly have come to play increasingly important
roles in clinical applications such as disease diagnostics,
monitoring therapeutic effects and predicting recurrence in
specific patient populations. Specifically, circulating miRNAs
have many characteristics of good biomarkers. (1) miR-
NAs are stable in the circulation and resistant to storage
handling, and serum miRNAs are resistant to RNase di-
gestion and other harsh conditions such as extreme pH,
boiling, extended storage, and multiple freeze-thaw cycles.
(2) Most miRNAs sequences are conserved across species.
(3) Changes in miRNA levels in circulation have been as-
sociated with different diseases as well as with certain bio-
logical or pathological stages. (4) miRNAs levels can easily
be determined by various methods [21-24]. Thus far, there
are few if any studies on the study of miRNAs in children
as biomarkers indicative of potential risk of cardiovascular
disease, and such void represents a unique opportunity for
the field [25,26].
Cellular communication
It is now firmly established that communications between
cells are essential for appropriate development and func-
tion. The classical modes of intercellular communication
involve cell junctions, adhesion contacts, and soluble fac-
tors that can act upon the same cell where they are pro-
duced, or upon neighboring cells, or may even act over
long distances in an endocrine manner [27]. Cells can
communicate directly with each other through cell-cell
contact or at a distance using secreted soluble mediators.
In multicellular organisms, cells can communicate via
extracellular molecules such as nucleotides, lipids, or pro-
teins. In addition, cells release various types of membranevesicles into the extracellular space that differ in origin,
size, morphology and content to best adapt to their sur-
rounding microenvironment. These extracellular vesicles
contain numerous proteins, lipids, and even nucleic acids
(Couzin, 2005), and are released in the extracellular space
and bind to receptors on other cells, thus modifying intra-
cellular signaling in the recipient cells. Cells may release
membrane vesicles into their extracellular environment ei-
ther by pocketing them off directly from the plasma mem-
brane or through secretion by endocytic compartments
[28]. These small, defined vesicles released by cells have
been variously termed”exosomes”,”microparticles”,”micro-
vesicles”, and”apoptotic blebs”, and their nomenclature is
strictly based on size, density, and membrane composition
(for more details see http://www.microvesicles.org/).
Extracellular vesicles contain defined patterns of mRNA,
miRNA, long non-coding RNA, and occasionally genomic
DNA, and therefore their contributions to cellular traffick-
ing consists in the transfer of genetic information that in
turn induces transient or persistent phenotypic changes in
the recipient cells [29,30]. Most circulating small RNAs
(sRNAs) are contained within lipids or lipoprotein com-
plexes, apoptotic bodies or exosomes that efficiently protect
them from degradation by serum ribonucleases. Several re-
ports have now demonstrated that RNAs contained within
exosomes can be transferred and modulate the function of
the recipient cells [29,31,32].
The important roles of extracellular vesicles in the
pathogenesis of various diseases have recently been the ob-
ject of substantial attention and research. These efforts
have been particularly focused on cellular communication
in the context of how organized sets of molecules may be
involved in many different cellular processes, have the cap-
acity to transmit antigenic information and can be easily
recovered from fluids. Another emerging area of discovery
that is not related to exosomes, and yet involves mecha-
nisms by which cells relay information to other cells, has
been the identification of long, thin, interconnecting mem-
branous bridges that connect neighboring cells through ad-
hesion mechanisms or tunneling nanotubes that can
establish direct tubular conduits between the cytoplasms
of adjacent cells [33]. Thus, both extracellular and intercel-
lular connectivities are emerging and providing a unique
opportunity to explore normal homeostatic processes, dis-
ease states, and therapeutics. Here we will review our
current understanding on exosomes, and how the latter
can serve in the context of cardiovascular disease risk iden-
tification and prevention in children.
Exosome biogenesis and compositions
Exosomes are one of several cell-secreted vesicles, which
include microvesicles, ectosomes, membrane particles,
exosome-like vesicle’s and apoptotic bodies. Exosomes ex-
hibit pleiotropic biological functions, including immune
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tion and the transfer of RNA and proteins. The features
and characteristics of the 3 major cell-derived microvesicle
types are listed in Table 1.
Exosomes are 30–100-nm diameter membrane vesi-
cles of endocytic origin that are released by most cell
types upon fusion of multivesicular bodies (MVB) with
the plasma membrane, presumably as a vehicle for cell-
free intercellular communication. Exosomes were first
described during the 1980s as organelles aimed at remov-
ing cell debris and unwanted molecules. For example, dur-
ing reticulocyte maturation the transferrin receptor and
many membrane-associated proteins were shed in small
membrane vesicles via an unknown secretory process
[37,38], essentially with exosomes functioning as cellular
garbage disposals. Since then, exosomes have emerged as
important mediators of cellular communication that are
involved in both normal physiological processes, such as
lactation [38], immune response [39], and development
and progression of diseases, such as liver disease [40], neu-
rodegenerative diseases [41], and cardiovascular disease
[42]. While the complete array of biological functions
played by exosomes remains unclear, they clearly mediate
communications between cells and facilitate processes
such as antigen presentation as well as trans-signaling to
neighboring cells [43].
Exosomes are secreted by many cell types, including B
cells [44], T cells [45], dendritic cells [46], mast cells [47],
platelets [48], and tumor cells [49]. In addition, exosomes
have been found in bodily fluids, including urine and am-
niotic fluid [50], serum [51], plasma [52], saliva [39], breast
milk [39,53], cerebrospinal fluid [54], and nasal secretions
[55], suggesting that these microvesicles may be exploited
as biomarkers in the diagnosis of disease [56,57].Table 1 Key features of the main extracellular vesicle populat
Feature Exosomes M
1-Size 40-100 nm 10
2-Markers CD63, CD9, Alix, and TSG101 An
se
3-Cell shapes Multivesicular bodies fusion
with plasmatic membrane
Me
4-Contents Proteins, RNA, and miRNA Pr
Me
5-Detection methods FACS with CD68 capture, electron microscopy,
Western blot for exosomes enriched markers
FA





7-Mechanism of release Exocytosis of MVBs Bu
References [34] [35Biochemical and proteomic analysis of exosomes further
uncovered that these vesicles contain, besides a common
set of membrane and cytosolic molecules, cell-type specific
proteins that characterize their functional activity [58]. The
mechanisms involved in protein sorting and loading into
the exosome are still under investigation, but clearly involve
ubiquitin and Endosomal Sorting Complex Required for
Transport (ESCRT) machinery in this process. Exosomes
are generated as intraluminal vesicles (ILVs) by a mechan-
ism of”reverse budding” of the limiting membrane of late
endosomes, which become multivesicular bodies (MVBs)
when their lumen contains ILVs. When MVBs fuse with
the plasma membrane, their cargo of ILVs is released to the
extracellular space, as illustrated in Figure 1. A number of
molecules are involved in the biogenesis and secretion of
exosomes such as the ESCRT complex which is responsible
for the sorting of proteins/cargos in the of MVBs [59]. Re-
cently, a ceramide-dependent mechanism via neutral sphin-
gomyelinase 2 (nSMase2) was proposed to be implicated in
the regulation of exosome secretion [60]. Other molecules
regulating the docking and fusion of MVBs with the plasma
membrane are Rab proteins and SNARE (Soluble NSF At-
tachment Protein Receptor) proteins [59].
Exosomes can interact with recipient target cells via differ-
ent mechanisms such as fusion with the plasma membrane
or adhesion to corresponding receptors on the plasma
membrane [61]. Several lines of evidence suggest that induc-
tion of intracellular calcium [61], overexpression of Rab11 or
citron kinase [62] as well as a reduction in membrane choles-
terol, or inhibition of cholesterol biosynthesis [63], could
stimulate the release of exosomes into the microenvironment.
Extracellular membrane vesicles, play important pleio-
tropic roles in many biological processes, and are enriched





Annexin , DNA, histones
mbrane blebbing Cell shrinkage and cell death
oteins, RNA, and miRNA
mbrane permeable
Cell organelles, proteins, DNA,
RNA, and miRNA
CS and electron microscopy FACS and electron microscopy
tracentrifugation (10,000- 60,000 g) No standardized method
dding from plasma membrane Cell shrinkage and plasma membrane
blebbing during cell death
] [36]
Figure 1 Schematic representation of extracellular vesicles (EVs) and the transfer of genetic material by exosomes. These EVs include
different types of membrane vesicles (apoptotic bodies [ABs], microparticles/microvesicles, and exosomes), which can be found in body fluids
including plasma and urine. The signals of extracellular vesicles can be activated through different steps based on environmental stimuli such as
stress or hypoxia. Extracellular signals activate the fusion of multivesicular bodies (MVBs) into the plasma membrane and foster the release of their
intraluminal vesicles (ILVs) as exosomes from the donor cells as illustrated in Panel (A). Once the exosomes are released and reach their targets
they will start to fuse with the recipient cells (Panel B). Some proteins are directed by the ESCRT (endosomal sorting complex required for
transport) machinery to the MVB route. Extracellular vesicles, which are secreted into the extracellular environment, contain functional molecules
that can be taken up by recipient cells through mechanisms that include fusion with the plasma membrane, phagocytosis and endocytosis. Panel
(C) represents the content of exosomes which contains a large array of proteins some of which are involved in membrane transport and fusion
(such as RAB proteins and annexins), cytoskeletal proteins, adhesion molecules and tetraspanins, lipid rafts, as well as RNA (mainly miRNA and
RNA), and DNA. Exosome membranes are enriched in lipid-based rafts such as cholesterol, ceramide and sphingolipids.
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tional factors. Of note, circulating miRNAs, for example,
are released from the parental cells to the extracellular mi-
lieu in highly stable forms, and in order to be protected
from degradation by extracellular RNases, these cellular
miRNAs can be released as soluble ribonucleoprotein com-
plexes or inside cell-derived vesicles. In blood, the majority
of cell-free miRNA is associated with the protein Argonaute
2 (AGO2), a main component of the RNA-induced silen-
cing complex (RISC). These AGO2–miRNA complexes
protect circulating soluble miRNAs from degradation by
RNases present in plasma.
The bioactive molecules contained in exosomes have
been suggested to (1) directly stimulate target cells via bio-
active lipids or by acting like soluble cell-surface signaling
complexes; (2) transfer oncogenic cargo and cancer cell
properties to proximate indolent or normal cells; and (3)
epigenetically reprogram recipient cells via the transfer
of mRNA, miRNAmicroRNA, and transcription factors.Exosomes can be transported between different cells and
influence physiological pathways in the recipient cells. Exo-
some composition varies depending on the cell type of ori-
gin. Recent information from different cell type reveals
that exosomes may contains a large variety of constitutive
elements. Indeed, 4,563 proteins, 194 lipids, 1639 mRNA
and 764 miRNA were identified in exosomes [34,64] dem-
onstrating their complexity and potential functional diver-
sity (see below).
Exosome protein composition
The protein composition of exosomes isolated from dif-
ferent cell sources has now been analyzed by different
techniques including proteomics, Western blots and flow
cytometry (FACS). These proteins essentially reflect both
the cell type from which they are secreted and their endo-
somal origin, as well as their possible physiological roles
and targeting properties [65,66]. Proteomic analysis of
exosomes generated from different cell types/lines and
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characteristic marker proteins on their surface or in their
lumen, which are proteins from the cytosol, the plasma
membrane, but also from the Golgi apparatus and endo-
plasmic reticulum [58,66,67] (see Figure 1). As illustrated
in Figure 1, the intercellular communication signals can be
stimulated based on environmental stimuli. The message
(s) transmitted by these intercellular communications may
include growth, division, survival, differentiation, stress re-
sponses, and apoptosis signaling. The apoptotic bodies can
be released as blebs of apoptotic cells, and they are charac-
terized by phosphatidylserine externalization and contain
fragmented DNA. Interestingly, exosomes can carry
complex biological information consisting of mRNAs,
miRNAs, as well as soluble and transmembrane pro-
teins between cells.
One important challenge in the study of exosomes has
been the lack of robust, reproducible isolation methods to
obtain highly pure and well-characterized vesicular popu-
lations. Several strategies have been used for exosome iso-
lation based on their size. There are 4 different methods
that have been proposed to isolate and characterize exo-
somes including: (1) ultra-centrifugation [68], (2) ultra-
filtration [69], (3) immunoprecipitation technologies with
the use of antibody-loaded magnetic cell beads [70], and
more recently (4) ExoQuick precipitation methods (System
Biosciences, Mountain View, CA, www.systembio.com, and
Life Technologies, Foster City, CA, www.lifetechnologies.
com), based on size-based precipitation approaches, a
process that is relatively short, requiring less than 2hours,
and proven to be efficient, reliable and reproducible when
compared to the other methods.
Exosomes can be produced by the endocytic and exocytic
activity in physiological and physiopathologic conditions
[71,72]. A number of proteins families were identified in
exosomes and many of these, such as heat shock proteins,
annexins, and proteins of the Rab family, are primarily in-
volved in intracellular assembly and trafficking of exo-
somes, and may not be required further after the vesicles
are secreted [71]. Other ubiquitous proteins are involved in
antigen presentation, as they can bind antigenic peptides
and participate in loading peptides onto MHC molecules
[73]. Tetraspanins are one of the most abundant protein
families that is found in exosomes, consisting of a large
number of transmembrane proteins. Several members of
this family, such as CD9, CD63, CD81 and CD82 are highly
enriched in exosomes. Tetraspanins interact with many
protein partners including MHC molecules and integrins,
suggesting that they are involved in the organization of
large molecular complexes and membrane subdomains
[66,74]. Integrins are another group of abundant proteins
detected in exosomes, where they exist as heterodimers of
α and β subunits, and function as adhesion molecules facili-
tating binding to the extracellular matrix [75].Exosome lipids composition
The lipid composition of mast cell-derived exosomes in-
cludes lysophosphatidylcholine, sphingomyelin, phosphat-
idylcholine, phosphatidylserine, phosphatidylethanolamine
cholesterol and diglyceride [76]. It has been indicated that
phosphatidylserine is a key determinant for the interaction
of membrane vesicles with target cells although oxidized
lipids which may also indicates that play a role. Phosphati-
dylserine and microparticles of different cellular origin can
bind to platelet CD36 scavenger receptor, leading to in-
crease ADP-dependent platelet activation and augmented
thrombosis in mice [77]. The phosphatidylserine-moiety
of endothelial microparticles can interact with endothelial
phosphatidylserine receptor in an annexin I–dependent
manner to prevent endothelial apoptosis [78]. It seems
that when comparing these lipids with their parent cells,
membranes of extracellular vesicles are enriched with
phosphatidylserine, disaturated phosphatidylethanolamine,
disaturated phosphatidylcholine, sphingomyelin, ganglio-
side GM3, and cholesterol [79,80]. These enriched lipids
as well as lipid-raft-associated proteins in vesicular mem-
branes provide extracellular vesicles with stability and
structural rigidity [81,82].
Exosome miRNAs composition
MicroRNAs (miRNAs) are non-coding RNA (19–22 nucle-
otides) that post-transcriptionally regulate gene expression
by base-pairing with the 3' untranslated region of comple-
mentary messenger RNA targets. As mentioned above,
miRNAs were found to be present in human plasma and
serum in a remarkably stable and cell independent form,
and their discovery has led to renewed interest in their use
as novel non-invasive biomarkers in the context of physio-
logical and pathophysiological conditions, including cancer
and cardiovascular disease [83-87]. In addition to the clas-
sical mechanisms such as direct cell-cell contact or chemical
receptor-mediated events, recent studies demonstrated that
the transfer of exosome-derived unique miRNAs to recipi-
ent cells is an alternative mechanism enabling gene-based
communication between cells [60]. Thus, RNA containing
exosomes may represent alternate pathways of cellular com-
munication with significant implications in the modification
of cell phenotypes in response to homeostatic pertubations.
As such, specific miRNAs such as let-7, miR-1, miR-15,
miR-16, miR-151 and miR 375 which play role in angiogen-
esis, hematopoiesis, exocytosis and tumorigenesis have been
reported in exosomes [74].
Exosome functions
To understand the biological function of exosomes, a num-
ber of transcriptomic and proteomic profiling analyses have
been performed [71,67,79]. Exosomes can activate or inacti-
vate different pathways on surrounding or remotely-located
cells, depending on their molecular composition, which is
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The assessment of biological functions of exosomes showed
that they can deliver specifically their cargo from the donor
to recipient cells. The molecular composition of exosomes
reflects the specialized function (s) of their original cells.
Through their ability to bind target cells, they are likely to
modulate selected cellular activities, such as vascular
homeostasis, and antigen presentation. The presence of
exosomes in blood and tissues in vivo, suggests their par-
ticipation in physiological and/or pathological processes,
such as stimulation of regulatory T-cell lymphocytes, induc-
tion of protection against allergic sensitization, induction of
cytokine production, and induction of tumor growth
[39,66,89-92].
Exosomes and endothelium
Exosomes are released from endothelial cells [93] and car-
diomyocytes [94,95]. Gupta and colleagues showed that the
levels of exosome-mediated secretion of HSP60 from adult
cardiomyocytes were increased three-fold in mild hypoxia
[95], and Waldenstrom and colleagues explored the mRNA
content of exosomes released from cardiomyocytes under
normal conditions, and identified 1,520 mRNA by micro-
array analysis [94]. In addition, proteomics analysis of endo-
thelial exosomes revealed about 1,354 distinctive proteins,
while microarray analysis revealed 1,992 mRNA tran-
scripts, and there were 21 of these transcripts in endothe-
lial exosomes that were altered in their abundance due to
hypoxia [93].
Studies of miRNAs are not only providing sources of
disease biomarkers [20], but also enabling greater under-
standing of cardiovascular development under normal
conditions and of remodeling processes in disease. In par-
ticular, miR-1, miR-133, miR-208, and miR-499 have been
reported to be highly expressed in cardiac tissue from the
early stages of heart development, regulating cell prolifera-
tion, differentiation, and apoptosis, as well as playing crit-
ical roles in several cardiac diseases [96]. Recent studies of
circulating miRNA-133a levels showed levels were in-
creased upon the onset of acute myocardial infarction, and
also elevated with unstable angina pectoris and Takotsubo
cardiomyopathy, even in the absence of elevation of serum
creatine phosphokinase or cardiac troponin, two standard
markers of acute cardiac insults [97].
Several reports using primary rodent cardiomyocytes
(in vitro) have provided evidence of exosome secretion
[95,98]. For example, Cheng and colleagues [99] detected
significantly higher levels of miR-1 and miR-208 in urinary
exosomes derived from acute myocardial infarction (MI)
patients and in the circulating blood of rats after acute MI.
Furthermore, the cardioprotective miR-214 that is se-
creted via exosomes from human endothelial cells has
been shown to be up-regulated in the heart after acute is-
chemia and also altered in the plasma of coronary arterydisease patients, indicating the severity of the disease. Re-
cent work from several laboratories including ours has
identified alterations in specific microvesicles in the
plasma that not only exhibit severity-dependent changes
but also provide suggestions as to the cellular sources of
such microvesicles and their potential implications in car-
diovascular disease in children [100-104].
Exosome transfer miRNAs
As mentioned above, exosomes have been found to con-
tain different RNAs, including mRNAs, miRNAs, and
long non-coding RNA (lncRNAs). In mammals, miR-
NAs can be transported by high-density lipoproteins
(HDLs) and be delivered to recipient cells to modulate
their function [105]. Inhibition of neuronal sphingo-
myelinase 2 (nSMase2), [32,106], increase the amount
of miRNAs exported to HDLs by blocking the release of
miRNA-loaded exosomes. Thus, nSMase2 and the cer-
amide pathway might regulate different but coordinated
pathways of miRNA secretion. Argonaute 2 (AGO2) is
considered the key effector protein of miRNA-mediated
silencing and can form circulating ribonucleoprotein
complexes with miRNAs [107,108].
The transfer of intact mRNAs from exosomes to target
cells may alter the phenotypic features of recipient cells.
Exosome-mediated RNA transfer is believed to be an effect-
ive method for cell signaling and the exosomal RNA will
certainly impact biological processes in the recipient cells
[32,60,109]. Exosomal RNAs have been implicated in many
exosome-mediated biological functions [110]. In addition,
exosomes are natural carriers of exogenous siRNA to hu-
man cells in vitro [111]. Therefore, the ability of exosomes
to naturally carry and deliver RNA between cells could be a
useful method to deliver therapeutic short interfering RNA
(siRNA) to the desired target cells. Studies have shown that
the packaging of RNAs into exosomes is selective because
the RNA profiles in exosomes do not fully reflect the RNA
profiles observed in the parental cells [29,31]. While exo-
somes have been shown to play functional roles in recipient
cells, the RNA content of the exosomes may provide
unique molecular signatures for disease diagnosis and prog-
nosis [112]. It has been reported that exosomes from dis-
eased individuals contained RNAs that were not found in
healthy subjects [50,112]. Recently, the role of miRNAs in
inflammation and metabolic and cardiovascular diseases
has been highlighted [113-115].
Exosome and the endothelial barrier
Endothelial dysfunction (ED), an early risk marker of cardio-
vascular disease, refers to a loss of normal homeostatic func-
tion in the blood vessels, and is characterized by altered
vasodilatory and vasoconstrictive functions and inflamma-
tory activity [116]. ED is an early and sustained process in-
volved in the development of vascular complications related
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tension, coronary artery disease and chronic heart failure
[117,118]. In healthy subjects, the vascular endothelium,
which forms the barrier between blood and the surround-
ing tissues, is known to efficiently respond to stress signals
like hypoxia and inflammation by adaptation of cellular
physiology and the secretion of cytokines and growth fac-
tors that recruit endothelial progenitor cells or cells that
play a role in the innate immune response [119]. Also, it
has been reported that endothelial cells secrete exosomes
[120,121] and several reports show that endothelial cells
can also be targeted by exosomes derived from different
cell types [122].
The tight junction complex is critically involved in the
exchange of ions, solutes, and cells that travel across para-
cellular spaces. Tight junctions regulate the formation of
apico-basal polarity and control proliferation, gene expres-
sion, or cell differentiation through signaling pathways
that are activated by tight junction components [123]. Sev-
eral proteins have been identified to be associated with
tight junctions [124] such as occludin (OCLN) and clau-
dins (CLD), and these are transmembrane spanning pro-
teins forming the intercellular adhesions via hemophilic
and heterophilic interactions. Zonula occludens-1 (ZO-1),
ZO-2, ZO-3, or cingulin, are located mintracellularly and
anchortransmembrane proteins with the actin cytoskeletonFigure 2 Schematic diagram illustrating the potential use of exosoma
(CVD (+)). Children with obesity, OSA, or both may be at increased risk of
from children with CVD (+) will differ from those children that do not exhi
candidate exosomal miRNAs can then be used as biomarkers for diagnostic[123]. Tight junction components, such as occludin, clau-
dins, or junctional adhesion molecules, are linked to the
actin cytoskeleton by ZO proteins, thereby enabling these
proteins to constitute major stabilizing factors of tight junc-
tions. Accordingly, ZO proteins have been shown to be es-
sential for tight junction formation [125]. Recent studies
now show that exosomes from patients with cardiovascular
disease or from endothelial cells exposed to stressful condi-
tions can disrupt endothelial tight junctions and reflect the
extent of endothelial dysfunction or of repair potential
[126-134].
In the context of OSA, in depth exploration of the exo-
somal content is lacking. Initial work on microvesicles and
OSA would definitely justify further efforts since a sub-
stantial degree of correlations between microvesicles from
different cellular sources and cardiovascular outcomes in-
cluding ED have been identified [135-145]. Similar obser-
vations are applicable in the context of obesity, whereby
specific microvesicles appear to be closely associated with
metabolic or cardiovascular outcomes [135-146]. Further-
more, children with obesity, OSA, or both may be at in-
creased risk of CVD, but their identification is currently
difficult. We postulate that exosomes isolated from chil-
dren with CVD (+) will differ from those children that do
not exhibit increased CVD risk (CVD (−)). Identification
and validation of candidate exosomal miRNAs can thenl miRNAs to identify children at risk for cardiovascular disease
CVD but currently their identification is difficult. Exosomes isolated
bit increased CVD risk (CVD (−)). Identification and validation of
purposes and potentially provide insights into therapeutic strategies.
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tially provide insights into therapeutic strategies. We
propose as illustrated in Figure 2, a schematic diagram il-
lustrating the potential use of exosomal miRNAs to iden-
tify children at risk for cardiovascular disease.
Exosomes in diagnosis and therapy
As discussed above, circulating cell-free nucleic acids have
promising potential as non-invasive diagnostic markers
for pathological processes such as chronic inflammation,
cancer and cardiovascular disease [147,148]. More re-
cently, have emerged as possible vehicles for the delivery
of therapeutic molecules, and have mainly been investi-
gated in the context of cancer therapy on account of their
T-cell stimulatory capacity. For instance, exosomes loaded
with tumor antigens have been shown to stimulate CD4+
and CD8 + T cell lmphocytes, and exosomes from in vitro
cultured antigen presenting cells (APCs) administrated in
vivo can induce T-cell lymphocyte responses resulting in
inhibition of tumor growth [149,150]. The first two prom-
ising phase I trials in human cancer have been published
[151,152] using exosomes from monocyte-derived DCs
loaded with tumor antigens. The use of exosomes in car-
diovascular diseases is being now intensively explored but
unlikely to be readily applicable in children.
Despite the relative facility to collect exosomes from
biological fluids, the actual use of exosome-derived pro-
teins or miRNAs as biomarkers is, however, not yet imple-
mented in clinical practice. Minimally invasive diagnostics
(based on analysis of blood) or non-invasive diagnostics
(using urine and saliva samples) are superior alternatives
to traditional needle or excision biopsies due to the re-
duced patient pain and inconvenience, and greater speed
and lower cost of analysis. Indeed, several companies have
initiated development of the exosome-based diagnostics
within the last three years. For example, a sensitive diag-
nostic of prostate cancer based on analysis of exosomal
proteins was recently launched (www.CarisLifeSciences.
com). Exosome diagnostics is developing biofluid-based
molecular diagnostic tests for use in personalized medicine.
The main focus thus far is on oncology or neurodiagnostics
through exosome-based technology platforms (www.Exo-
someDx.com; www.HansaBioMed.eu). We propose that
similar to some of the proteomic biomarkers emerging in
the context of pediatric sleep apnea and cardiovascular dis-
ease [153-157].
Conclusion
Cells communicate with each other via extracellular
molecules, such as nucleotides, lipids, miRNA, or pro-
teins. These molecules can then be released extracellu-
larly by cells in microvesicles and bind to receptors on
other cells, thus inducing intracellular signaling and
modification of the intracellular physiological state ofrecipient cells. Exosomes have been isolated and charac-
terized from many different biological fluids such as blood
components, urine, amniotic fluids, malignant effusions,
breast milk and bronchoalveolar lavage fluid and contain
an array of proteins and lipids as well as genetic material
such as mRNA and miRNA. The unique opportunities for
the discovery and use of exosomes contents as clinical bio-
markers of cardiovascular disease risk in obese children or
in other groups of children with diseases associated with
cardiovascular morbidities such as pediatric sleep apnea
appears to be warranted. Indeed, the study of exosomes in
the context of pediatric obesity or OSA will illustrate novel
mechanisms of cell–cell and organ–organ communica-
tion, identify novel biomarkers of the disease and its com-
plications, and potentially aid in the development of novel
therapeutics.
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